Pointing to a concurrent cis mechanism of action, experimental evidence in CTLA-4−/− mice carrying human CTLA-4 suggested that anti-CTLA-4 mAb would need to bind to both Teff and Treg cells to produce full tumor protection (15). Here, CTLA4 is linked to neoplasm.